Literature DB >> 28946544

Successful return to play following adductor longus proximal tendon rupture in professional soccer without re-injury at 12 months: A case report.

Ömer B Gözübüyük1,2, Maarten H Moen3, Mehmet Akman2, Ioakim Ipseftel2, Agah Karakuzu4.   

Abstract

Treatment of total ruptures of adductor longus is challenging in professional sports. Time for return to pre-injury level as well as re-injury rates are of concern and surgical and conservative treatment approaches are debated; yet no consensus approach described for professional athletes. We present a case of a professional soccer player who experienced a rupture in his left adductor longus proximal tendon during a game and was treated conservatively. This case was followed-up during clinical assessment, imaging and strength testing until and after return to play. Primary outcome measure was the return to standard play condition at his pre-injury level without any functional deficits, measured by isokinetic testing. Second outcome measure was the recurrence. No recurrence was observed during the first year of follow-up. Total ruptures are very challenging for both the physician and the player to make a quick decision due to minimal or lack of pain. Functional outcomes are almost identical although operative treatments need longer time to return to play. This case report adds another example to the literature of a successful return to play after non-operative treatment of adductor longus rupture at elite level soccer.

Entities:  

Keywords:  Total rupture; groin pain; platelet rich plasma; return to play; soccer

Mesh:

Year:  2018        PMID: 28946544     DOI: 10.3233/BMR-170857

Source DB:  PubMed          Journal:  J Back Musculoskelet Rehabil        ISSN: 1053-8127            Impact factor:   1.398


  1 in total

1.  The clinical efficacy of using autologous platelet-rich plasma in total hip arthroplasty: A retrospective comparative study.

Authors:  Xi Wang; Jianbin Ma; Zhiyuan Wang; Lin Xiao
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.